Although a number of studies have demon strated the neuroprotective effects of antagonists of postsynaptic N-methyl-D-aspartate (NMDA) and non NMDA receptors in cerebral ischemia, little is known about the treatment of cerebral infarction through presyn aptic blocking of extracellular glutamate release. We evaluated the effects of a presynaptic selective N-type calcium channel antagonist (SNX-ll1, given intrave nously by continuous infusion at 5 mg/kg/h from 20 min prior to occlusion until 2 h postocclusion) on blood flow, extracellular glutamate, and infarct volume in rats with permanent occlusions of the right middle cerebral and right common carotid arteries plus I-h transient occlusion of the left common carotid artery. There was no signifi cant difference in CBP in the occluded cortex during the
It has been shown that extracellular glutamate or other excitatory amino acid neurotransmitters in crease massively during cerebral ischemia (Ben veniste et ai., 1984; Hagberg et ai., 1985; Shimada et ai., 1989) . Elevated glutamate levels in the extra cellular space increase the concentration of intra cellular calcium through the activation of N-methyl D-aspartate (NMDA), non-NMDA, and metabotro pic receptors and subsequently lead to irreversible neuronal damage (Choi, 1985; Rothman and Olney, 1986; Choi et ai., 1988; Mayer and Miller, 1990) . A number of studies have demonstrated the neuropro-tective effects of postsynaptic NMDA receptor an tagonists (Simon et ai., 1984; Park et ai., 1988; Tak izawa et ai., 1991) and postsynaptic non-NMDA re ceptor antagonists (Sheardown et aI., 1990; Nellgard and Wieloch, 1992) . However, pathomor phological and psychotomimetic adverse effects of NMDA receptor antagonists in rats have raised concerns regarding their clinical utility (Olney et ai., 1989 (Olney et ai., , 1991 .
Another strategy to reduce neuronal damage in ischemia is to inhibit the release of glutamate from presynaptic sites. It is generally accepted that, upon depolarization of the plasma membrane, glutamate is released from synaptosomes in a Ca2+ -dependent manner and from the cytoplasm in a Ca2 + independent manner by reversal of the uptake path way (Nicholls and Sihra, 1986; Nicholls et ai., 1?87; Sanchez-Prieto et ai., 1987; Smith and Augustine, 1988; Szatkowski et ai., 1990; Katayama et ai., 1991) . It is also known that the calcium channels at some presynaptic nerve terminals mediating cal-cium-dependent transmitter release are predomi nantly N-type channels (Miller, 1987; Smith and Augustine, 1988; Tsien et aI., 1988) . The N-type channel has been distinguished from the other classes of calcium channels by its sensitivity to the w-conopeptide GVIA, found in the venom of the fish-eating marine snail Conus geographus (Cruz and Olivera, 1986; McCleskey et aI., 1987) . The neuroprotective efficacy of the w-conopeptide GVIA has not been extensively studied, and its characteristic irreversible binding to the N-type voltage-sensitive calcium channels (VSCCs) re stricts the potential clinical utility (Kasai et aI., 1987) . However, the synthetic peptide SNX-III, corresponding to the structure of the w-conopeptide MVIIA from C. magus (Olivera et aI., 1987) , which is also a potent and specific N-type channel antag onist, was found to be a highly effective neuropro tective agent. Recently, Valentino et al. (1993) re ported that SNX-ll I protected pyramidal CAl neu rons in the hippocampus from damage caused by transient forebrain ischemia in rats, and this neuro protective efficacy did not correlate with blocking of glutamate release from presynaptic sites. How ever, it has not been studied whether SNX -111 pro duced its neuroprotective action via reduction of glutamate release from presynaptic sites in focal ce rebral ischemia. Therefore, we evaluated the effects of SNX-ll1 in focal ischemia on CBF, extracellular glutamate, and infarct volume in focal ischemia us ing the hydrogen clearance method, an in vivo brain microdialysis technique, and 2,3,5-triphenyltetra zolium chloride (TTC) staining, respectively.
MATERIALS AND METHODS

Focal cerebral ischemia
The surgical and anesthetic procedures were approved by the Animal Experimentation Committee, School of Medicine, Tokai University.
Male Sprague-Dawley rats (Charles River Japan Co., Kanagawa, Japan), weighing -350 g, were used in this study. Animals were fasted overnight but allowed free access to water. On the day prior to the experiment, fol lowing induction of anesthesia with 1.5% halothane, a microdialysis probe (Eicom Co., Kyoto, Japan) with a tubular dialysis membrane (3 mm long and 0.2 mm in diameter) and a platinum electrode (UHE-IOO, 0.1 mm in diameter, insulated up to I mm of the tip; Unique Medical Co., Tokyo, Japan) were assembled with a tip-to-tip dis tance of I mm. The probe/electrode assembly was placed stereotaxically through a burr hole in the cortex supplied by the right middle cerebral artery (MCA) territory (an teroposterior bregma -3.5, lateral 4.0, depth 5.0 mm at 30° laterally from the sagittal plane). This probe/electrode position corresponded to the center of the area of the eventual infarction that was demonstrated as the non stained region by TTC staining. Simultaneously, a ther mocouple probe (52K/J thermometer; John Fluke Mfg.
J Cereb Blood Flow Metab. Vol. 15, No.4, 1995 Co., Everett, WA, U.S.A.) was placed into the subdural space through the same burr hole to measure brain tem perature. On the day of the experiment, the rat was anes thetized with 1.5% halothane, and polyethylene catheters (PE-50) were placed in both femoral arteries for physio logical monitoring and one femoral vein for drug admin istration. The reference electrode was inserted under the skin of th<! neck. The rat was then tracheostomized, par alyzed with pancuronium bromide (0.6 mg/kg i.v.), and ventilated with a mixture of 30% oxygen170% nitrous ox ide/0.5% halothane. Focal cerebral ischemia was achieved using the method described by Chen et aI. (1986) . Briefly, a burr hole, 2 mm in diameter, was made 1 mm rostral to the anterior junction of the right zygoma and squamosal bone. The distal portion of the MCA above the rhinal fissure was ligated with a double-square knot using a 10-0 silk suture. This was immediately fol lowed by permanent ligation of the right common carotid artery (CCA) and temporary clip compression of the left CCA for 60 min. The skin over the head wound was su tured. All reasonable efforts were made to minimize any discomfort to the experimental animals. During the ex periment, brain and rectal temperatures were controlled at -37°C with an external heating lamp and a heating pad, respectively. These temperatures and MABP were con tinuously monitored. Arterial gases, blood glucose level, and hematocrit were examined preocclusion and at 30 and 90 min after occlusion.
Experimental design
Animals were divided into three experimental groups: Group 1 (n = 8) was given SNX-lll (a gift from Neurex Corp., Menlo Park, CA, U.S.A.) dissolved in saline by intravenous continuous infusion at 5 mg/kg/h from 20 min prior to the occlusion until 2 h postocclusion. Group 2 (n = 9) was the vehicle-treated group with the same occlu sion, but given saline alone at the same infusion rate as group 1. Group 3 (n = 7) was a sham-operated group in which the MCA and both CCAs were exposed but not occluded. All animals were decapitated 4 h after occlu sion.
Previous experiments have shown that SNX-l11 has a neuroprotective action in global ischemia when given by bolus intravenous infusion of 5 mg/kg (Valentino et aI., 1991; Smith and Siesj6, 1993) . Our preliminary study has demonstrated that the continuous intravenous infusion of SNX-ll1 at 5 mg/kg/h reduced MABP from 123 ± 7 to 90 ± 9 mm Hg in normal rats (n = 6) (which is statistically significant by paired t test, p < 0.05), but did not cause a statistically significant reduction in cerebral circulation. On the basis of these observations, this dose of SNX-lll was applied in the current study.
In vivo microdia1ysis and CBF measurement
The microdialysis probe in the cortex was perfused with Ringer solution (155 mM NaCI/5.5 mM KC1J2.3 mM CaCI2), which was warmed to -36°C, through the dialysis probe at a rate of 2.0 f.lllmin using a syringe pump (EF-80; Eicom Co., Kyoto, Japan), and the dialysates were col lected at lO-min intervals into plastic tubes for 40 min before to 4 h after occlusion and then frozen at -70°C. Stable basal concentrations of extracellular glutamate were detected in three consecutive samples collected be fore occlusion. Analysis of glutamate concentrations in the dialysates was performed by HPLC and fluorescence detection after precolumn derivatization with o-phthaldi aldehyde (Lindroth and Mopper, 1979) . The glutamate response was calibrated with an external standard. Peak areas in glutamate were determined by a blinded ob server.
Regional CBF was measured by the hydrogen dear ance method using a digital tissue blood flow meter (dig ital UH-meter model NMG-Dl; Unique Medical Co., To kyo, Japan). After a 10% hydrogen gas mixture was ad ministered for 2 min, a hydrogen clearance curve was charted. The CBF was calculated from the clearance curve according to the formula of Aukland et al. (1964) .
Determination of infarct volume
Four hours after occlusion of MCA plus CCAs, the rat was perfused with 0.01 M phosphate-buffered saline (pH 7.2) through the descending aorta under anesthesia. The brain was then removed and cooled in ice-cold normal saline for 5 min and dissected in the coronal plane at 2-mm intervals starting at 3 mm from the frontal tip. The brain slices were incubated in 2% TTC in phosphate buffered saline at 37°C for IS min and then stored in 10% neutral-buffered formalin (Bederson, 1986a,b; Liu et aI., 1989) . Both surfaces of the 2-mm-thick TTC-stained sec tions were photographed using color slide film. In each rat, the volume of infarct in the cerebral cortex was de termined by the method of Swanson et al. (1990) using a computer-assisted image analysis system (MCID, Imag ing Research, St. Catherine's, Canada). Briefly, this method consists in measuring the volume of normal gray matter in specific structures of both hemispheres, then subtracting them, thus avoiding direct measurement of the infarct region, which may be distorted by edema. The lowest optical density of gray matter in the nonoccluded cortex was designated as the threshold value, and the numbers of pixels within the outlined cortex on the isch emic and nonischemic sides with optical densities above this threshold were then calculated in each available brain section. The volume of noninfarcted cortex was then cal culated by multiplying each area by the distance between sections. The infarct volume was determined as a per centage of the difference between the left and right vol umes normalized to the volume of the structure in the control cortex. The measurement of infarct size was car ried out with the examiners blinded as to the animal's experimental status. To verify the infarcted area in this model, several brain sections selected at random were stained with hematoxylin and eosin.
Statistical analysis
The statistical differences in physiological parameters including MABP among groups were evaluated by one way analysis of variance (ANOYA) followed by Scheffe's mUltiple comparison. The data on CBF, extracellular glu tamate concentrations, and infarct volumes were as sessed by two-way repeated ANOY A with factors and time. To assess further differences among groups, one way ANOY A followed by Scheffe's multiple comparison was used. The changes in brain and rectal temperatures, MABP, CBF, and glutamate values before and after the administration of SNX-l11 in the SNX-ll1-treated group were analyzed by paired t test. All values were expressed as means ± SD.
RESULTS
Physiological parameters
Brain and rectal temperatures, arterial blood gases, blood glucose, and hematocrit levels in the three groups are shown in Table I . There was no significant difference in any of these functions be tween vehicle-and SNX-Ill-treated groups during the experiment. Furthermore, paired t test revealed no significant influence of SNX-III administration on brain and rectal temperatures. A small but sig nificant drop in brain temperature occurred preis chemia and at 0 min of ischemia in the SNX -111treated group compared with the values in the sham-operated group. Significant changes in rectal temperature at 30 min of ischemia and in blood glu cose preischemia in the vehicle-treated group were observed, compared with those in the sham operated group.
The changes in MABP in the three groups are given in Fig. I . SNX-III administration signifi cantly reduced preischemia MABP from 123 ± 7 to 96 ± II mm Hg in the SNX-Ill-treated group (paired t test, p < 0.001). MABP at 0 min of isch emia was 136 ± 14, 145 ± 14, and 107 ± 19 mm Hg in the sham-operated, vehicle-treated, and SNX Ill-treated groups, respectively. There were signif icant differences in MABP at 0--70 min after occlu sion between the vehicle-and SNX-111-treated groups (one-way ANOVA followed by Scheffe's multiple comparison). Overall assessment by two way repeated ANOV A for MABP also revealed sig nificant differences for group (F1,7 = 35.0, P < 0.0001) and time (F I 4•98 = 2.9, P < 0. 01) between vehicle-and SNX-ll1-treated groups.
CBF
The changes in cortical CBF are given in Fig. 2 . Preischemia CBF was 93-107 ml 100 g -I min -I with no statistically significant difference among the three groups (one-way ANOVA followed by Scheffe's multiple comparison). Preischemia CBF was unchanged by SNX-111 perfusion (paired t test). The values of cortical CBF at 0 min of isch emia in vehicle-and SNX-111-treated groups were 6. 8 ± 5. 6 and 5.7 ± 6.8 ml 100 g-1 min -1 , and the CBF values after unclipping the left CCA (at 60 min of ischemia) reached 11.2 ± 8.9 and 12.8 ± 10.1 ml 100 g -1 min -1 , respectively. Essentially no signif icant difference was observed in CBF after occlu sion between vehicle-and SNX-ll1-treated groups (two-way repeated ANOV A). We confirmed that the probe/electrode in all r ats was located in the center of the area of the eventual infarction of the MCA territory, which was demon strated as the nonstained region by TTC staining. Extracellular glutamate treated groups, respectively. These concentrations were not significantly different. SNX-lll adminis tration did not change extracellular glutamate levels preischemia (paired t test). After ischemia, extra cellular glutamate concentrations in the vehicle- Figure 3 shows the extracellular glutamate values in the three groups. Extracellular glutamate levels preischemia were 0. 7 ± 0. 7,1. 2 ± 1.0, and 1. 0 ± 0.9 j.LM in the sham-operated, vehicle-, and SNX-lll- Values are means ± SO. SNX-111 signifi cantly reduced preischemia MABP from 123 ± 7 to 96 ± 11 mm Hg in the SNX-111-treated group (paired t test, ap < 0.001). Significant differences in MABP at 0-70 min after oc clusion are observed between vehicle-and SNX-111-treated groups (*p < 0.001). For abbreviations see the text. .1· .. · ·· · . . r " \� ·· ····0 ' · ' --0--Ischemla+SNX·lll min of ischemia reached 6.8 ± 5.6 and 5.7 ± 6.8 ::::' ml 100 g -1 min -\ and CBF after unclipping the I left CCA (60 min after occlusion) increased slightly and. reached 11.2 ± 8.9 and 12.8 ± 10.1 ml 100 g-1 min-1 in the vehicle-and SNX-111treated groups, respectively. No significant difference was observed in CBF after occlusion between vehicle-and SNX-111-treated groups
(two-way repeated ANOVA). For abbreviations see the text. 
Infarct volume
The percentage volume of cortex infarcted in the ischemic hemisphere of the vehicle-and SNX-11l treated groups in TTC-stained sections is shown in Fig. 4 . Compared with the vehicle-treated group, infusion of SNX-ll1 significantly reduced the total volume of cortical infarction, estimated by integra tion, from 47.2 ± 5.8 to 19.9 ± 7.3% of normal cortical volume (F1,1 5 = 67.8, P < 0.0001 by two way repeated ANOV A). The percentage infarct area determined by staining with hematoxylin and eosin was similar to that obtained in TTC-stained sections,
DISCUSSION
Excessive release of glutamate is thought to play a major role in the susceptibility of neurons to dam age by ischemia. Our investigation arose from the hypothesis that the inhibition of glutamate release from presynaptic sites can protect neurons from subsequent histological damage in focal ischemia.
Our results demonstrate that a specific N-type VSCC antagonist, SNX-111, administered intrave nously at 5 mg/kg/h from 20 min prior to occlusion until 2 h postocclusion, significantly reduced the extracellular glutamate level compared with that in rats with focal ischemia receiving vehicle infusion. Baseline levels of extracellular glutamate at preis chemia may decrease after administration of SNX-111. However, the levels appeared to be unchanged during preischemia, suggesting that any such de crease may be too small to be detected by the method we used. SNX-111 significantly reduced the volume of cortical infarction from 47.2 ± 5.8 to 19.9 ± 7.3% at 4 h after occlusion. The CBF during isch emia was not significantly changed by the infusion of SNX-111, which suggests that this neuroprotec tive effect is not related to vasodilation. On the other hand, SNX-l11 significantly reduced preis chemia MABP from 123 ± 7 to 96 ± 11 mm Hg. This phenomenon can be considered to be caused by systemic vasodilation due to inhibition of nor epinephrine release in peripheral nerves by SNX-111 (Bowersox et aI., 1992) . Although systemic hy potension is generally disadvantageous in maintain ing collateral flows around cerebral infarction, a slight decrease of MABP may not be a critical prob lem for clinical use. The fact that infarct volume was reduced despite mild systemic hypotension in dicates that SNX-l11 might be a highly efficacious neuroprotective agent. A slight drop in brain tem perature preischemia and at 0 min of ischemia in the J Cereb Blood Flow Metab, Vol. 15. No.4, 1995 SNX-111-treated group was observed compared with the values in the sham-operated group. It has been reported that significant difference in infarct volume was not demonstrated between the 30 and 36°C groups in rats with permanent MCA occlusion (Morikawa et aI., 1992) . We therefore speculate that such mild hypothermia (35.7 ± 0.3°C in rats receiv ing SNX-111 compared with 36.0 ± 0.6°C in vehi cle-treated rats) is not likely to affect any of the results in this study, including extracellular gluta mate, CBF, and infarct volume. It is unclear whether the dose of SNX-ll1 (5 mg/ kg/h) we used is optimal. Valentino et al. (1993) have carried out dose-response studies to evaluate SNX-111's efficacy when the peptide was adminis tered intravenously either 1 or 6 h after global isch emia. Increasing neuroprotection was provided by doses up to 15 mg/kg under both conditions. The dose of SNX-l11 required for reducing damage to the CAl subfield by 50% compared with saline treated controls was 2.3 mg/kg for animals receiving the peptide 6 h after global ischemia. Our prelimi nary results indicated that >5 mg/kg/h of SNX-l11 reduced MABP to <90 mm Hg. Furthermore, higher doses may be needed when SNX-111 is ad ministered intravenously presumably so that suffi cient material crosses the blood-brain barrier to achieve appropriate brain concentrations. We therefore considered that the dose of 5 mg/kg/h of SNX-111 might be high enough to be efficacious without causing severe systemic hypotension, but further studies to determine the appropriate dose of SNX-ll1 in focal ischemia would be desirable.
The elevation of extracellular glutamate during ischemia may be caused by several mechanisms, including Ca2 + -dependent exocytotic release from a transmitter pool, Ca2+ -independent release from a cytoplasmic pool, and/or decreased glutamate up take at the nerve terminals or glial cells in ischemia (Miller, 1987; Smith and Augustine, 1988; Maycox et aI., 1990) . Katayama et al. (1991) reported that the early rapid increase in glutamate appears to be a result of Ca2 + -dependent exocytotic release from the nerve terminals, and the later slow increase is produced in part by Ca2+ -independent processes. In this study, SNX-l11 significantly reduced the peak value of the extracellular glutamate from 44.2 ± 15.8 J.LM (mean ± SD) to 21.4 ± 11.4 J.LM at 50 min of ischemia. We speculate therefore that SNX-111 inhibits the calcium-dependent exocytotic re lease from a transmitter pool by blocking the N-type VSCCs. Calcium-independent release from a cytoplasmic pool, however, may remain after SNX-111 administration, although our results can not rule out the possibility that the administration of SNX-l11 at 5 mg/kg/h is not enough to block gluta mate release completely.
To our knowledge, this is the first report to ex amine in detail the effects of selectively blocking N-type VSCCs presynaptically in a focal ischemia model. However, a few studies concerning the treatment of cerebral infarction through blocking excitatory amino acid release have been reported. Cyclohexyl adenosine decreased neurotransmitter release by blocking presynaptic Al receptors and protected against neuronal death in global ischemia (von Lubitz et ai., 1988) . w-Conotoxin GVIA, which has been shown to block N-type VSCCs, could inhibit dopamine release in global ischemia (Ooboshi et al., 1992) . BW1003C87, which inhibits sodium channel function, has neuroprotective ef fects due to decreasing depolarization-induced glu tamate release in focal cerebral ischemia (Graham et al., 1993) . These results support the hypothesis that the inhibition of glutamate release from presyn aptic sites can prevent neuronal damage.
The ischemia model we used required occlusion of the distal right MCA and the right CCA plus 1-h transient occlusion of the left CCA as described by Chen et al. (1986) . This model allows us to make a consistent cortical infarction that is limited to the cortex by ligation of the distal portion of the MCA and to measure CBF using a hydrogen clearance method at any time without electrical coagulation (Chen et al., 1986) . The probe/electrode used to measure extracellular glutamate and CBF was lo cated in the center of the area of the eventual in farction, which was demonstrated as the non stained region by TTC staining. Our results using this elec trode indicate that the CBF in the center of the area of infarction at 0 min of ischemia was 6.8 ± 5.6 and 5.7 ± 6.8 ml 100 g-I min -I, and the CBF after unclipping in the left CCA reached 11.2 ± 8.9 and 12.8 ± 10.1 ml 100 g-I min -I in the vehicle-and SNX-111-treated groups, respectively. Thus, par tial reperfusion after unclipping of the left CCA will occur even in the center of the area of the infarc tion, although this model is generally regarded as one of permanent occlusion. Furthermore, studies using 1 2 5 I-Iabeled SNX-111 administered intrave nously have shown that �0.03% of the radioactive peptide can be found in the brain (Valentino et al., 1993) . Thus, a higher dose of SNX-111 and/or the breakdown of the blood-brain barrier may be nec essary to supply SNX-ll1 to ischemic tissue. We therefore consider that the collateral circulation partially supplying the ischemic cortex may contrib ute to carrying SNX-111 into the tissue after the breakdown of the blood-brain barrier, besides the administration of SNX-111 prior to occlusions.
In conclusion, these studies indicate that SNX-111 is potentially useful as a therapeutic agent in cerebral infarction, despite some uncertainty as to the most effective dose to be used and the spectrum of the drug's actions.
